Medigen Biotechnology Corp. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 205.57 million compared to TWD 191.57 million a year ago. Net loss was TWD 97.33 million compared to TWD 122.77 million a year ago. Basic loss per share from continuing operations was TWD 0.7 compared to TWD 0.88 a year ago.
For the six months, sales was TWD 369.81 million compared to TWD 676.28 million a year ago. Net loss was TWD 192.03 million compared to TWD 204.48 million a year ago. Basic loss per share from continuing operations was TWD 1.38 compared to TWD 1.47 a year ago.